Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasia.
نویسندگان
چکیده
PURPOSE We evaluated the urodynamic and clinical effects of terazosin in patients with symptomatic benign prostatic hyperplasia (BPH). MATERIALS AND METHODS A total of 45 patients who participated in a multicenter trial was evaluated with urodynamic pressure-flow studies before and after 26 weeks of treatment. RESULTS Maximum flow rate and symptom score improved significantly in 22 patients with and 11 without bladder outlet obstruction who completed 26 weeks of treatment. In patients with bladder outlet obstruction the condition was significantly reduced and in patients without obstruction, significant urodynamic changes could not be detected. CONCLUSIONS Terazosin treatment results in symptomatic relief and improved urinary flow in patients with and without bladder outlet obstruction, and in significant improvement in patients with urodynamically proved obstruction.
منابع مشابه
The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia.
OBJECTIVES To evaluate the cost-effectiveness and functional status effects of terazosin, an alpha(1)-adrenoceptor antagonist, compared with placebo in the treatment of men with moderate to severe, symptomatic, benign prostatic hyperplasia (BPH). METHODS Prospective, randomized, double-blind, placebo-controlled multicenter trial of 2084 patients was conducted at 15 academic regional centers a...
متن کاملMedical therapy for benign prostatic hyperplasia: a review of the literature.
OBJECTIVE To review the existing evidence regarding the efficacy and safety of medical therapy for lower urinary tract symptoms (LUTS) indicative of benign prostatic hyperplasia (BPH). To assess randomised controlled trials investigating the six alpha-adrenergic receptor antagonists (alpha-blockers), prazosin, alfuzosin, indoramin, terazosin, doxazosin, and tamsulosin, that benefit patients by ...
متن کاملLong-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group.
OBJECTIVES To evaluate long-term efficacy and safety of terazosin, a selective alpha 1 blocker, in the treatment of benign prostatic hyperplasia (BPH). METHODS This was a long-term (42 months), open-label, multicenter study with patients evaluated at 1- to 6-month intervals. Twenty-three outpatient clinics throughout the United States and Canada participated in the study. A total of 494 men w...
متن کاملEarly Efficacy of Tamsulosin Versus Terazosin in the Treatment of Men With Benign Prostatic Hyperplasia: A Randomized, Open-Label Trial
Background: We evaluated the efficacy and tolerability of tamsulosin versus terazosin in patients with signs and symptoms of benign prostatic hyperplasia (BPH). Methods: Patients (N = 1,993) were randomized to tamsulosin (0.4 mg/day) or terazosin (5 mg/day, following titration). The primary efficacy endpoint was total American Urological Association Symptom Index (AUA-SI) score after 4 days of ...
متن کاملComparative analysis of resected prostate weight in diabetic and non-diabetic benign prostatic hyperplasia patients
Background: Benign prostatic hyperplasia (BPH) is the most common benign tumor in men. The etiology of BPH is still unresolved and multiple systems are likely to be involved. The effects of diabetes on urinary system are a risk factor for BPH. We then assessed the effects of diabetes on the parameters related to BPH, especially weight and volume. Methods: This study was conducted on patients...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- The Journal of urology
دوره 155 4 شماره
صفحات -
تاریخ انتشار 1996